大脑高通量多omics数据揭示了阿尔茨海默氏症疾病中的分子异质性
Abdallah M Eteleeb1,2, Brenna C Novotny1, Carolina Soriano Tarraga1
1Department of Psychiatry, Washington University, Saint Louis, St. Louis, Missouri, United States of America.
PLoS biology
|April 30, 2024
概括
机器学习整合了阿尔茨海默病 (AD) 的多原子数据,以找到四个分子概况. 一个概况与严重的AD进展,神经退行和改变的途径有关,提供了新的生物标志物.
科学领域:
- 神经科学是一个神经科学.
- 基因组学就是基因组学.
- 生物标志物发现发现
背景情况:
- 阿尔茨海默病 (AD) 呈现出显著的分子异质性.
- 了解这种异质性对于开发有效的诊断和治疗方法至关重要.
- 多原子方法为疾病复杂性提供了全面的了解.
研究的目的:
- 整合多原子数据 (转录组,蛋白组,代谢组,脂组) 与人类AD队列中的临床和神经病理学数据.
- 识别与疾病进展和严重程度相关的独特分子概况.
- 为了发现潜在的脑脊液 (CSF) 生物标志物来监测AD.
主要方法:
- 应用机器学习来整合来自多个人类AD队伍的高通量omics数据.
- 与临床结果,神经病理学和Braak tau分数相关的分子概况.
- 使用单核RNA测序 (snRNA-seq) 来识别细胞类型的特定贡献.
- 用SNCA小鼠模型进行交叉omics分析,以保存签名.
主要成果:
- 在阿尔茨海默病中发现了四个独特的多式联络分子概况.
- 一个特征与认知能力差,快速进展,生存时间缩短,严重的神经退行以及代谢特征改变有关.
- 这种特征显示了与突触相关的基因,内细胞结合,细胞体和mTOR信号通路在疾病阶段的失调.
- 识别了与SNCA小鼠模型重叠的分子签名.
- snRNA-seq揭示了介导这些分子形状的特定细胞类型.
- 发现了与已识别的多式联运集群相关的CSF潜在生物标志物.
结论:
- 多原子数据集成揭示了阿尔茨海默病的不同分子亚型.
- 一个特定的分子形状与侵袭性疾病进展和神经退行症密切相关.
- 确定了特定细胞类型的途径和潜在的CSF生物标志物,用于监测AD进展和认知.
相关概念视频
01:26Alzheimer's Disease: Overview
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ and tau...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:29Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...
01:23Alzheimer Disease ll: Pathophysiology
Alzheimer disease involves structural changes in the brain that begin long before symptoms appear. The most distinctive features are extracellular neuritic plaques and intracellular neurofibrillary tangles.Neuritic plaques form in the cerebral cortex and around blood vessels. These plaques contain a dense core of beta-amyloid (Aβ)—a toxic protein fragment that clumps outside neurons. The core is surrounded by damaged neuronal extensions, as well as reactive astrocytes and microglia. Abnormal...
01:22Dementia l: Introduction
Dementia is an acquired, progressive syndrome characterized by a decline in multiple cognitive domains severe enough to impair daily functioning and reduce independence. Although memory loss is a central feature, the diagnosis requires additional deficits involving language, executive function, visuospatial skills, judgment, calculation, or abstract reasoning. These cognitive impairments reflect underlying neurodegenerative or vascular processes that gradually disrupt neuronal networks...